White paper: Advantages of Antibody-based Selectivity in the Purification of Next Generation Biologics

It has been almost 40 years since the first biologic drug reached the market. That drug was human insulin, which was produced by cloning human genes into E. coli for protein expression at a scale suitable for therapeutic use. Today, biologics are expected to be the fastest-growing segment of the pharmaceutical industry, reaching a predicted worth of $1.2 trillion by 2030.

Because biologic drugs are produced in living systems, it is critical that they are separated from potentially harmful contaminants or impurities such as host cell proteins, cell debris, and any other impurities before being dosed in man. However, established purification techniques employ lengthy protocols and often incur substantial product losses, leading many biologics manufacturers to seek a more viable alternative.

In this white paper you will learn more on: 

  • The benefits of affinity chromatography for the purification of novel biologics
  • How the CaptureSelect™  technology supports biotherapeutic development
  • Real case studies demonstrating the use of  CaptureSelect™ affinity chromatography

Download the Document

    Please fill out the information below to request information on the products you selected. If you are already registered, or have requested a quote before, and this information will be filled out for you.

  • Please enter your first and last name.

  • Please enter the name of the company or institution you work at.

    Please enter your job title.

  • Please enter your mailing address.

  • Please enter the e-mail address you would like to be contacted at.

  • Please enter the phone number you would like to be contacted at.

  • Thermo Fisher is here to help you succeed in taking your discovery to commercial realization. Would you like to have a technical expert contact you to learn more about our affinity chromatography solutions?

  • I would like to receive information about events, products, services, and promotions from Thermo Fisher Scientific and its affiliates: I agree for the Thermo Fisher Scientific group thermofisher.com/legalentities to contact me by email and telephone to inform me of events, products, services, and promotions offered in connection with the brands Thermo Scientific™, Applied Biosystems™, Invitrogen™, Gibco™, Ion Torrent™, Unity Lab Services™, Fisher Scientific™. I can withdraw my consent and unsubscribe at any time by emailing [email protected] By submitting my data, I give consent to the collection, processing and use of my personal data in accordance with the Thermo Fisher Scientific Privacy Policy.

  • By submitting this form, you consent to American Pharmaceutical Review storing your email address and contact information, transmitting your contact information to selected trusted partners, and customizing your experience based on the data you enter. You can also stay up-to-date on the latest news, new technologies, and more delivered to your email inbox by selecting your subscription preferences on the next page.